血清胸腺因子对放化疗保护作用的实验研究

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (1): 70-73.

血清胸腺因子对放化疗保护作用的实验研究

李湛军, 廖晓全, 徐康森

中国药品生物制品检定所生化药品与基因工程药物室, 北京 100050

收稿日期:2005-09-19 修回日期:2005-10-31 出版日期:2006-01-06 发布日期:2020-10-23
通讯作者: 李湛军, 通讯作者, 女, 医学博士, 副主任药师, 研究方向:生化药理与生物检定。 Tel:010-67095464 E-mail:zhanjunqq@yahoo .com .cn E-mail:zhanjunqq@yahoo .com .cn
作者简介:李湛军, 通讯作者, 女, 医学博士, 副主任药师, 研究方向:生化药理与生物检定。 Tel:010-67095464 E-mail:zhanjunqq@yahoo .com .cn

Experimental study on radioprotective and cytoprotective activities of fac- teur thymic serique in mice

LI Zhan-jun, LIAO Xiao-quan, XU Kang-sen

Department of Biochemical Drug and Genetic Engineerning Pharmaceutical National Institute for the Control of Pharmaceu- tical and Biological Products, Beijing 100050 , China

Received:2005-09-19 Revised:2005-10-31 Online:2006-01-06 Published:2020-10-23

摘要/Abstract

摘要： 目的 :观察血清胸腺因子在对抗辐射和抗化疗副作用方面的作用。方法:抗辐射实验:KM 小鼠, 共 6 组, 除空白组外, 其它小鼠接受钴( Co) 60 照射后, 模型组皮下( S .C .) 注射 0 .1 ml 生理盐水, FTS 低、中、高剂量组分别S .C .注射FTS 0 .025 、0 .25 、2 .5 mg·kg ^-1, 每天一次, 连续 7 d ;阳性药组于实验 d 1 一次性口服灌胃尼尔雌醇 2 .5 mg·kg ^-1 , 检测免疫活性;对分别接受 Co60 的 600 或 700 拉德辐射小鼠, 记录30 d 内存活率。抗化疗副作用实验:对肝癌 H22 细胞的荷瘤小鼠, 当日腹腔注射环磷酰胺 100 mg·kg -1 , 同时各组给药, 每天一次, 连续 19 d, 记录 20 d 内小鼠存活率。结果 :小鼠经辐射后, 与模型组比较, FTS 各剂量组白细胞总数、对碳粒的吞噬速率和吞噬指数、胸腺系数显著提高( P <0 .05) ;脾脏系数比尼尔雌醇组的脾脏系数略高( P >0 .05) ;对 700 拉德的辐射小鼠, 与模型组比, FTS 0 .25 mg·kg ^-1组 30 d 内存活率显著增加( P <0 .05) 、平均存活天数明显延长( P <0 .01) , 与阳性药组一致。荷瘤小鼠接受环磷酰胺化疗, 皮下注射 FTS 给予荷瘤小鼠经化疗后的 20 d 内存活率增加。结论:血清胸腺因子具有抗辐射、抗化疗副作用, 前景广阔。

关键词: 血清胸腺因子, 抗辐射, 免疫系统, 荷瘤小鼠, 化疗, 存活率

Abstract: AIM :To evaluate the radioprotective ef- fects and cytoprotective activities of the facteur thymic se- rique ( FTS) to reduce certain side-effects in the chemo- therapy in mice .METHODS:Except of control group, all mice which received acute whole-body Co-60-gamma irradiation were randomized to 5 groups :Saline solution was given to model group, 0 .025, 0 .25, and 2 .5 mg·kg ^-1·day ^-1 for 7 consecutive days FTS to low or me- dial or large dose of FTS group by s .c., 2 .5 mg·kg ^-1 nilestriol to control drug group by i .g .at 1st day and the radioprotective efficacy of FTS was determined by immuni- ty effects and by measuring 30-day survival at 6 .0 Gy or 7 .0 Gy .The same doses above of FTS were investigated by measuring 20-day survival at 100 mg·kg ^-1 d-1 for 14 consecutive days cyclophosphamide injury in mice with H22 liver cancer cell for its cytoprotective activities to re- duce certain side-effects in the chemotherapy of cancer. RESULTS :The leucocyte total number, phagocyte com- petence and thymus index were enhanced significantly when compared with the model group ( P <0 .05) , but spleen index increased than those of nilestriol group ( P > 0 .05) .Thirty-day survival for 0 .25 mg·kg ^-1 FST ad- ministered mice at 7 .0 Gy was significantly increased in comparison with saline administered mice ( P <0 .05) and the survival days were longer ( P <0 .01) , the same as nilestriol group .20-day survival was increased for FST to inhibit cyclophosphamide-induced injury in mice with tumors .CONCLUSIONS:FTS developed in our labora- tory provides significant protection from acute whole-body gamma irradiation or chemotherapy ( cyclophosphamide) injury in mice .It may play an important role in the mani- festation of its radioprotective and cytoprotective efficacy .

Key words: facteur thymic serique ;radioprotective , immunostimulatory effects ;mice with tumors ;side-effects in the chemotherapy ;survival rate

中图分类号:

R965 .1

李湛军, 廖晓全, 徐康森. 血清胸腺因子对放化疗保护作用的实验研究[J]. 中国临床药理学与治疗学, 2006, 11(1): 70-73.

LI Zhan-jun, LIAO Xiao-quan, XU Kang-sen. Experimental study on radioprotective and cytoprotective activities of fac- teur thymic serique in mice[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(1): 70-73.

参考文献

1 张符光, 刘佃辛.胸腺和胸腺素研究进展[ J] .国外医学免疫学分册, 1996 ; 4: 187 -91
2 Pleau JM, Dardenne M, Blouquit Y.Structural study of circulat- ing thymic factor: A peptide isolated from pig serum[ J] .J Biol Chem, 1977; 152: 8045 -7
3 Chang WP, Marsh JA . The effect of synthetic thymulin on cell surface marker expression by avian T cell precursors[ J] . Comp Immunol, 1993 ; 17: 85-96
4 VillaVerde DMS, Dfresne MP, Vannier-dos Santos MA. Identifi- cation of nuclear triiodothyronine receptors in the thymic epithe- lium[ J] . Endocrinol, 1992 ; 131: 1313-20
5 Merlino P, Marsh JA.Evidence for the diret action of thymulin on avian NK cells[ J] . Develop Comp Immunol, 2001 ; 25 : 337 -
43
6 Mocchegiani E, Santarelli L, Muzzioli Ml.Reversibility of the thymic involution and of age-related peripheral immune dysfunc- tions by zinc supplementation in old mice[ J] . Int J Immunop- harmacol, 1995; 17:703 -18
7 Chandratilleke D,Marsh GA. The effect of thymulin on avian IL-
2 receptor expression[ J] . Int J Immunopharmacol, 2000; 22 : 887 -96
8 Saha AR, Hadden EM, Hadden JW. Zinc induces thymulin se- cretion from human thymic epithelial cells in vitro and augments splenocyte and thymocyte responses in vivo[ J] . Int J Immunop- harm, 1995; 7 : 729-33
9 Chang WP, Marsh JA. The effect of synthetic thymulin on cell surface marker expression by avian T cell precursors[ J] . Comp Immunol, 1993 ; 17: 85-96
10 新药( 西药) 临床前研究指导原则汇编( 药学药理学毒理学)[ M] .中华人民共和国卫生部药政局, 1993 : 128-9
11 寇丽筠, 顾可梁.临床基础检验学[ M] , 北京.人民卫生出版社, l997: 51
12 Wu SH, Sun JF, Guo SZ.Experimental study on regulatory effect of compound gengniankang on endocrine and immune functions in aged female rats with osteoporosis[ J] .中国中西医结合杂志, 2004; 24 : 545-8
13 赵文仲, 沈建良.甾体雌激素在放射损伤性造血重建中的作用机理[ J] .中华放射医学与防护杂志, 1991; 11 : 8-9
14 Kobay ashi H, Abe H , Ueyama T , Awaya A.Radioprotective effects of serum thymic factor in mice[ J] .Radiat Res, 1992; 129: 351-6
15 Kobay ashi H , Abe H , Awaya A , Inano H , Shikita M. Serum thymic factor as a radioprotective agent promoting survival after X-irradiation[ J] . Experientia, 1990 ; 46: 484-6

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[4]	吴蓉蓉, 陈智强, 贾翼菲, 陈宏绮, 王盼盼, 燕茹. 靶向抑制肠道菌β-葡萄糖醛酸苷酶在肿瘤预防和治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(8): 964-974.
[5]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[6]	赵全凤, 符佩姝, 谷文睿, 郑丹, 吕宗杰, 杨洋. GnRHa用于化疗后生育力保护的循证医学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1449-1454.
[7]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[8]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[9]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[10]	唐慕菲, 沈芸竹, 张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 817-822.
[11]	赵妙惠，周佳妮，漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407.
[12]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.
[13]	徐伟平，周维英. 膀胱癌化疗药物增敏机制研究进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1060-1064.
[14]	李荣振，梅家转，夏云展，季节. 真实世界中R0切除术后结直肠癌患者接受卡培他滨为基础辅助化疗的预后影响因素及安全性探讨[J]. 中国临床药理学与治疗学, 2019, 24(6): 704-711.
[15]	郑中秋，谢伯剑，崔斌斌，柯抒晨，林义. miR-106 b在乳腺癌组织中的表达及其增强乳腺癌细胞顺铂化疗敏感性的机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 541-545.